4-[(2-甲酰基苯氧基)甲基]-苯甲酸甲酯 | 351335-29-0

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-[(2-甲酰基苯氧基)甲基]-苯甲酸甲酯
• 中文别名: 4-(2-甲酰基-苯氧基甲基)苯甲酸甲酯
• 英文名称: methyl 4-((2-formylphenoxy)methyl)benzoate
• 英文别名: 4-(2-Formyl-phenoxymethyl)-benzoic acid methyl ester；methyl 4-[(2-formylphenoxy)methyl]benzoate
• CAS: 351335-29-0
• 化学式: C₁₆H₁₄O₄
• mdl: MFCD01893190
• 分子量: 270.285
• InChiKey: USZUSRQZXDALNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险标志：
  GHS05
• 危险性描述：
  H318
• 危险性防范说明：
  P280,P305 + P351 + P338
• 海关编码：
  2918990090
• 包装等级：
  III
• 危险类别：
  8
• 危险品运输编号：
  1759
• 储存条件：
  -20°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 4-(2-Formylphenoxymethyl)benzoate
Synonyms: 4-(2-Formylphenoxymethyl)benzoic acid methyl ester

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 4-(2-Formylphenoxymethyl)benzoate
CAS number: 351335-29-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C16H14O4
Molecular weight: 270.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-[(2-甲酰基苯氧基)甲基]-苯甲酸甲酯 在 盐酸 、 三乙酰氧基硼氢化钠 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 methyl 4-((2-((4-((2-(3,3-difluorocyclobutyl)acetyl)glycyl)piperazin-1-yl)methyl)phenoxy)methyl)benzoate
  参考文献：
  名称：

  鉴定具有适当性质的有效埃博拉病毒进入抑制剂，用于体内研究

  摘要：

  先前的研究确定了金刚烷二肽哌嗪3.47，其通过靶向必需受体Niemann–Pick C1（NPC1）抑制埃博拉病毒（EBOV）感染。3.47的理化特性限制了其在体内测试的潜力。通过提高效力，降低疏水性和取代不稳定部分进行优化，确定为3.47具有改善的体外ADME特性的衍生物，对EBOV感染也具有很高的活性，包括在50％正常人血清（NHS）存在下进行测试时。此外，3A4被认为是代谢这些化合物的主要细胞色素P450亚型，因此，在存在CYP3A4抑制剂ritonavir的存在下进行测试时，小鼠微粒体的稳定性得到了显着改善，该药物已被批准用于临床作为抗HIV药物的增强剂。EBOV抑制剂与利托那韦的口服给药产生的药代动力学特征支持了用于小鼠功效研究的双向给药方案。

  DOI：

  10.1021/acs.jmedchem.8b00704
• 作为产物：
  描述：

  对氯甲基苯甲酸 在 硫酸 、 potassium carbonate 、 potassium iodide 作用下， 以 乙腈 为溶剂， 反应 4.0h， 生成 4-[(2-甲酰基苯氧基)甲基]-苯甲酸甲酯
  参考文献：
  名称：

  一种有效的白细胞迁移阻滞剂：GT-73 对 LPS 诱导的小鼠 ARDS 具有保护作用

  摘要：

  我们最近开发了一种分子 (GT-73)，它可能通过影响血小板内皮细胞粘附分子 (PECAM-1) 功能来阻止白细胞从血液跨内皮迁移到外周组织。GT-73 在 LPS 诱导的急性呼吸窘迫综合征 (ARDS) 小鼠模型中进行了测试。其基本原理是基于这样的发现：COVID-19 患者的死亡部分是由白细胞大量迁移至肺部引起的 ARDS 造成的。此外，还研究了叔丁基和甲酯部分在GT-73生物效应中的作用。应用人白细胞跨内皮迁移测定来验证 GT-73 衍生物的阻断效果。最后，使用 LPS 诱导的 ARDS 小鼠模型来评估 GT-73 的组织学和生化作用。获得的结果表明GT-73具有独特的结构，这决定了其生物活性；它的两个化学部分（叔丁基和甲酯）对于这种效果至关重要。GT-73 是一种前药，其亲脂性尾部通过 Lys536 与 PECAM-1 共价结合。GT-73 显着减少肺部浸润白细胞的数量并降低炎症水平。最后，GT-73

  DOI：

  10.3390/molecules26154583

文献信息

• [EN] SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION<br/>[FR] COMPOSÉS BENZALDÉHYDE SUBSTITUÉS ET PROCÉDÉS D'UTILISATION DE CEUX-CI DANS L'AUGMENTATION DE L'OXYGÉNATION DES TISSUS
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2013102142A1

  公开（公告）日：2013-07-04

  Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.

  提供了替代苯甲醛及其衍生物，其作为血红蛋白的变构调节剂，以及其制备的方法和中间体，包括这些调节剂的药物组合物，以及在治疗由血红蛋白介导的疾病和需要增加组织氧合的疾病中使用它们的方法。
• [EN] BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE POUR LE TRAITEMENT D'UNE INFECTION PAR FILOVIRUS
  申请人：CENTRE NAT RECH SCIENT

  公开号：WO2018050771A1

  公开（公告）日：2018-03-22

  The present invention relates to compounds comprising a benzimidazole scaffold, and the use of such compounds for the treatment of viral diseases. The invention also relates to pharmaceutical compositions comprising said compounds as an active ingredient. In particular the compounds of the invention comprising a benzimidazole scaffold are used for the treatment of filoviruses or retroviruses, and preferably for the treatment of Ebola virus or HIV virus.

  本发明涉及含有苯并咪唑骨架的化合物，以及利用这些化合物治疗病毒性疾病。该发明还涉及包含上述化合物作为活性成分的药物组合物。特别是，本发明涉及含有苯并咪唑骨架的化合物用于治疗丝状病毒或逆转录病毒，尤其是用于治疗埃博拉病毒或艾滋病毒。
• Novel inhibitors of leukocyte transendothelial migration
  作者：Tamar Getter、Raanan Margalit、Shirin Kahremany、Laura Levy、Eliav Blum、Netaly Khazanov、Nimrod Y. Keshet-Levy、Tigist Y. Tamir、M. Ben Major、Ron Lahav、Sofia Zilber、Hanoch Senderowitz、Paul Bradfield、Beat A. Imhof、Evgenia Alpert、Arie Gruzman

  DOI：10.1016/j.bioorg.2019.103250

  日期：2019.11

  synthesized, and tested in vitro for their capacity to block the transendothelial migration of immune cells. One of the molecules, namely, methyl 4-((2-(tert-butyl)-6-((2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene) methyl) phenoxy) methyl) benzoate, (compound 12), completely blocked leukocyte transendothelial migration, without any toxic effects on immune or endothelial cells (IC50 = 2.4 µM). In vivo

  白细胞跨内皮迁移是发起炎症性免疫反应的最重要步骤之一，而慢性炎症会导致毁灭性疾病。白细胞迁移抑制剂被认为是治疗炎性和自身免疫性疾病的有前途且潜在有效的治疗剂。在这项研究中，基于先前基于亚三磷酸四氢嘧啶的整合蛋白抑制剂，亚整合蛋白抑制剂最优化地阻断了白细胞的粘附，设计，合成并测试了十二种具有修饰支架的分子，它们在体外具有阻断免疫细胞跨内皮迁移的能力。分子之一，即4-（（2-（叔丁基）-6-（（（2,4,6-三氧四氢嘧啶-5（2H）-亚烷基）甲基）苯氧基）甲基）苯甲酸甲酯，（化合物12），完全阻断了白细胞的跨内皮迁移，而对免疫细胞或内皮细胞没有任何毒性作用（IC 50  = 2.4 µM）。在体内，化合物12在炎症性肠病（IBD）/克罗恩病，多发性硬化症，脂肪肝疾病和类风湿性关节炎模型中显示出显着的治疗作用。铅化合物在体内的详细急性和慢性毒性概况未显示任何毒性作用。因此，这种类型的分子可能为设
• [EN] NOVEL BARBITURIC ACID DERIVATIVES, THEIR PREPARATION AND USE THEREOF AS LEUKOCYTE TRANSMIGRATION INHIBITORS AND FOR TREATING INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES AND CANCER<br/>[FR] NOUVEAUX DÉRIVÉS D'ACIDE BARBITURIQUE, LEUR PRÉPARATION ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA TRANSMIGRATION DE LEUCOCYTES, LE TRAITEMENT DE MALADIES INFLAMMATOIRES, DE MALADIES AUTO-IMMUNES ET DU CANCER
  申请人：UNIV BAR ILAN

  公开号：WO2019043706A1

  公开（公告）日：2019-03-07

  Provided herein are novel barbituric acid derivatives, their synthesis and use thereof in blocking leukocyte transmigration. The novel barbituric acid derivatives are useful for the treatment of disorders associated with leukocyte transmigration, such as for example inflammatory diseases and disorders, autoimmune diseases and disorders, and cancers.

  本文提供了新型巴比妥酸衍生物，它们的合成以及在阻断白细胞迁移中的用途。这些新型巴比妥酸衍生物可用于治疗与白细胞迁移相关的疾病，例如炎症性疾病和疾病、自身免疫疾病和疾病以及癌症。
• COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
  申请人：Global Blood Therapeutics, Inc.

  公开号：US20170174654A1

  公开（公告）日：2017-06-22

  Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

  本文提供的是适用于调节血红蛋白的化合物和药物组合物，它们的制备方法和中间体，以及在治疗由血红蛋白介导的疾病和需要组织和/或细胞氧合的疾病中使用它们的方法。